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Abstract
Playing an important role in the etiology of substance use disorder (SUD), dopamine (DA) neurons are subject to
various regulations but transcriptional regulations are largely understudied. For the first time, we report here that the
Human Immunodeficiency Virus Type I Enhancer Binding Protein 2 (HIVEP2) is a dopaminergic transcriptional
regulator. HIVEP2 is expressed in both the cytoplasm and nuclei of DA neurons. Therein, HIVEP2 can target the intronic
sequence GTGGCTTTCT of SLC6A3 and thereby activate the gene. In naive rats from the bi-directional selectively bred
substance-preferring P vs -nonpreferring NP rat model of substance abuse vulnerability, increased gene activity in
males was associated with the vulnerability, whereas decreased gene activity in the females was associated with the
same vulnerability. In clinical subjects, extensive and significant HIVEP2-SLC6A3 interactions were observed for SUD.
Collectively, HIVEP2-mediated transcriptional mechanisms are implicated in dopaminergic pathophysiology of SUD.
Introduction
Many environmental factors can regulate dopaminergic
(DAergic) activity including SLC6A3, the gene encoding
the dopamine transporter (DAT)1–7. These regulations
remain mechanistically poorly understood. A critical step
in dissecting these mechanisms is to identify what tran-
scription factors (TFs) target the DAergic genome.
Recently, several TFs for SLC6A3 have been cloned,
including Nurr1 (NR4A2), paired-like homeobox 3 pro-
tein (PITX3), HEY1, SP1, SP3, AZI23′UTR, SRP54, and
Nfe2l18–13. It is postulated that HEY1 is a TF targeting the
3′UTR14, whereas the others appear to target 5′ promoter
regions except AZI23’UTR, a long noncoding RNA
(lncRNA), that regulates Intron 1 of SLC6A3. Among
these TFs, Nurr1, but not PITX3, is implicated in Par-
kinson’s disease15,16 and AZI23′UTR is implicated in sub-
stance use disorder (SUD)13. Importantly, both diseases
are closely associated with altered DAergic activity. These
findings indicate that identification of DAergic TFs may
provide opportunities for dissecting signaling pathways
that target these TFs for genomic action. This would help
clarify molecular cascades underlying neuronal develop-
ment, plasticity and DAergic transcription-related dis-
orders such as SUD17–20.
The present study focused on delineation of new tran-
scription mechanisms in SUD, using SLC6A3 as a pro-
totype target to clone DAergic TFs. Previous studies,
including ours, have shown that a 121-bp fragment in
Intron 1 of SLC6A3may display cis-acting activity in vitro.
This 121-bp fragment served as the bait/target in our
search for new DAergic TFs related to SUD.
Materials and methods
All DNA or RNA oligonucleotides used in this study are
shown in Table 1.
Cloning of TFs via Yeast One Hybrid System (Y1H)21
The 121-bp fragment of haplotype A22 was used as the
search target and a human adult brain cDNA library was
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constructed into pP6, a pGADGH derivative plasmid,
both used in Y1H in the search for proteins targeting the
121-bp (Hybrigenics Services, Paris, France). The bait
construct was first checked by re-sequencing and then
transformed into the yeast strain Y1H300 (MAT a, Gal4Δ,
ade2-101, trp1-901, leu2-3,112, his3Δ200), integrating the
DNA bait into the yeast genome. Screening was per-
formed against the random-primed cDNA library. Clones
were screened and complete cDNAs were cloned as
described before12.
Plasmid construction
Human HIVEP2 cDNA ORF (7.3 kb) was cloned by
PfuUltra High-fidelity DNA Polymerase (Agilent Tech-
nologies) chain reaction (PCR) and then ligating the PCR
product into the indicated sites in the mammalian
expression vector pcDNA3.1+, resulting in the plasmid
pcDNA3.1+HIVEP2. The cloning PCR used primers for
NheI (NEB)/NotI (NEB) sites-directed insertion. The PCR
templates were cDNAs synthesized from total RNAs
isolated from a combination of human SK-N-AS, IMR-32,
and SH-SH5Y cells23. PCR fidelity was verified by DNA
re-sequencing.
For luciferase (Luc) assay13, three reporter plasmids
were generated: 1, 2A and 2B. For constructing each
plasmid, two complementary single-stranded synthetic
oligonucleotides were annealed together into a double-
stranded oligonucleotide with NheI at the 5′ end and XhoI
(NEB) at the 3′ end, followed by ligation of the double-
stranded oligonucleotide to the same restriction sites
immediately upstream of the SV40 promoter in Promega’s
pGL3 Promoter Vector.
Cell culture and transfection
SK-N-AS and BE(2)-M17 cell lines were purchased
from ATCC and maintained in Dulbecco’s modified
eagle’s medium (DMEM, Gibco) containing 10% fetal
bovine serum (FBS, Atlanta Biologicals) and 1% Pen/Strep
(Gibco). One percent non-essential amino acids (Hyclone)
were added to medium for SK-N-AS. Cells were incu-
bated at 37 ˚C in humidified air with 5% CO2. Cell lines
were verified by PCR genotyping and tested for or
removed of mycoplasma contamination (Biotool Myco-
plasma Removal Kit, Bimake).
Cells were transfected chemically with plasmid DNA in
Polyethylenimine (PEI, Polysciences) or lipfectamine2000.
Plasmid DNA and PEI were diluted in DMEM without
serum separately. The PEI solution was then added into
the DNA solution, followed by vortexing for 10 s and
incubation at room temperature (RT) for 15min to form
DNA-PEI complexes. At the end, the complexes were
added to each well containing fresh 2% FBS growth
medium. Medium was changed into fresh 10% FBS
complete growth medium the next day. For 2-hexyl-4-
pentynoic acid (HPA, ApexBio) treatment, HPA was
added into cell medium 2 h after transfection at 5 µM/
well. Sixteen hours after transfection, cells were collected
Table 1 Oligonucleotide List (DNA and RNA)
Name Sequence AC
a. cDNA cloning (Figs. 3, 4b)
HIVEP2 forward 5′-aaaaagctagcaacaaaatggacactggggacaca-3′
HIVEP2 reverse 5′-aaaaagcggccgcatcaatgtagctgactcttttctgat-3′
b. Plasmid construction (Fig. 4b,d)
1-forward 5′-CTA GAG AAA GCC ACG-3′
1-reverse 5′-TCG ACG TGG CTT TCT-3′
2A-forward 5′-CTA GGG AGA GGC AAA-3′
2A-reverse 5′-TCG ATT TGC CTC TCC-3′
2B-forward 5′-CTA GGG AGG AGC AAA-3′
2B-reverse 5′-TCG ATT TGC TCC TCC-3′
c. HIVEP2 DsiRNA (Fig. 4c)
Sense 5′-GGUCUGGAGAAACUGAUAAAGCATC-3′
Antisense 5′-GAUGCUUUAUCAGUUUCUCCAGACCUU -3′
d. qRT-PCR primers (Figs. 3b–d, 5)
SLC6A3 forward 5′-ATC TAT GCG GCC TAC AAG TT-3′ 2.002
SLC6A3 reverse 5′-CTC TAC ACC TTG AGC CAG T-3′
hGAPDH
forward
5′-AGG CCG GAT GTG TTC G-3′ 2.017
hGAPDH
reverse
5′-TTA CCA GAG TTA AAA GCA GCC-3′
rHIVEP2 forward 5′-CTT CCT GTC CAC CTC ACT T-3′ 2.027
rHIVEP2 reverse 5′-CCA GAC CTG ACC TCG TCT A-3′
rDAT forward 5′-TCA CTC TTG GCA TTG TCC TG-3’ 1.972
rDAT reverse 5′-GAG CAC GCC AAA GAG GAT AG-3′
rGAPDH
forward
5′-ATG ACT CTA CCC ACG GCA AG-3′ 2.034
rGAPDH reverse 5′-TAC TCA GCA CCA GCA TCA CC-3′
e. ChIP-PCR (Fig. 2)
HIVEP2-DNPi
forward
5′-ACA TTA TTG AAT GCT CTT AGA AG-3′
HIVEP2-DNPi
reverse
5′-GCC TCA AGA CAG ACA CTC T-3′
hDAT+ 0.79 kb
forward
5′-TCG TCG GGT GTT TTA CCC AC-3′
hDAT+ 0.79 kb
reverse
5′-GTG GAG GCT CTA ACA GGC AA-3′
hACTB forward 5′-AAA GGC AAA CAC TGG TCG GA-3′
hACTB reverse 5′-GGG ACT CAA GGC GCT AAC TG-3′
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for quantitative reverse transcription PCR (qRT-PCR).
Three separate experiments were performed for statistical
analysis at least.
Animals
All animals, rats (alcohol preferring or P rat and alcohol
non-preferring or NP rat, generation 76 and 79 from
Indiana University) or male mice (C57BL/6NTac, from
Taconic Biosciences, Rensselaer, New York, USA), were
all adults (2–4 month old) housed under constant tem-
perature- (21 ˚C) and humidity- (50%) on a 12 h/12 h
light-dark cycle (light 07:00–19:00) with food and water
available ad libitum. Rodents were housed in plastic
ventilated cages. Mice housed up to five per cage, and rats
housed up to two per cage. No animal was housed singly.
Four individuals were used in each experiment for sta-
tistical analysis at least. All experimental procedures were
approved by the Institutional Animal Care and Use
Committees of McLean Hospital or the Indiana University
Schools of Dentistry and Medicine (Indianapolis, IN) and
were in accordance with the guidelines of the Institutional
Animal Care and Use Committee of the National Institute
on Drug Abuse, National Institutes of Health, and the
Guide for the Care and Use of Laboratory Animals.
Indicated sample size was determined by gene activity
stability without randomization/blinding involved for
molecular analyses.
Immunofluorescent staining (IFS) of cells and rodent brain
sections
Rabbit anti-HIVEP2 sera were kindly provided by
Shunsuke Ishii of Institute of Physical and Chemical
Research (RIKEN) in Japan. Methods were as described
before12. For SK-N-AS cell staining, coverslips were
blocked in 7% non-fat milk at RT for 1 h. Coverslips were
incubated with rabbit ant-HIVEP2 sera (1:50 diluted in
0.01% BSA in Tris buffered saline (TBS)) or with diluted
normal rabbit serum (Gibson Bioscience) as control at
4 ˚C for 48 h. The secondary antibody is Alexa Fluor 568
goat anti-rabbit IgG (1:500 diluted, RRID AB_143157,
Invitrogen). Images were obtained by confocal laser
scanning microscopy (Leica TCS SP8).
For mouse or rat brain section staining, adult animals
were anaesthetized with 250mg/kg Avertin (Acros
Organics) by intraperitoneal (i.p.) injection. Brains were
promptly collected and frozen. Before slicing, the brain
was fixed in 4% PFA at 4 ˚C for 24 h and was cryopro-
tected in 15% (wt/v) sucrose overnight and then in 30%
(wt/v) sucrose until the brain sank. After being embedded
in optimal cutting temperature (OCT) compound, the
frozen brain was coronally sectioned at 20 µm on a
cryostat (Thermo, Microm HM 505 E). Coronal sections
containing the substantia nigra and the ventral tegmental
area (VTA) were selected and washed three times, 5 min
each, with 0.01M PBS for free floating staining. The
sections were incubated with 0.3% Triton X-100 (diluted
in PBS) for 30min first, from the blocking step, the
treatments were the same as those for cells, using mouse
monoclonal anti-Tyrosine Hydroxylase (TH, 1:800 diluted
in TBS containing 0.01% BSA, Millipore) for a marker of
dopaminergic neurons.
Western blotting
Western blot analyses were performed on protein
fractions from cultured cells, or VTA of adult mice and
rats as method described before13. In HIVEP2 siRNA
experiment, cells were transfected with lipfectamine2000
according to the manufacturer’s instructions. 50pmol
DsiRNA was applied in each well. Cells were lysed 48 h
after transfection by adding 100 µL/well of RIPA buffer
(Gendepot) supplemented with protease inhibitor cocktail
(Millipore). Five cycles of sonication (5 s on and 5 s off)
were applied for nuclear protein. Protein concentration
was determined by BCA (Bicinchoninic acid) kit (Thermo
Scientific) according to the manufacturer’s instruction.
For rodents, adult animals were killed by decapitation,
brains were promptly collected and dissected in metal
matrix (RWD). Two millimeters thick coronal brain sec-
tion containing VTA between matrix 19 and 21mm
(bregma −4.52 to −6.8 mm) was cut and collected for rat
brains; 1 mm thick coronal brain section between matrix 8
and 9mm (bregma −2.92 to −3.88 mm) was cut-collected
for mouse brains. VTA was sliced out of the section at one
third from ventral side in the horizontal plane by
removing overlying cortex and hippocampus at the
periphery.
Cytoplasm and nuclear proteins of the VTA were
separated using Lysis Buffer J from Cytoplasmic &
Nuclear RNA purification Kit (Norgen Biotek) according
to the manufacturer’s instructions. Nuclei were pelleted
(4 ˚C, 12,000 × g for 10 min) and washed three times with
cold PBS while the supernatants were collected as cyto-
plasm protein samples. RIPA buffer supplemented with
protease inhibitor cocktail was used to lyse the nuclei as
described above, the supernatants were collected as
nuclear protein fractions.
Fifty µg total protein per loading well was electro-
phoretically separated on a 4–15% Criterion TGX precast
gel (Bio-Rad). Polyvinylidene difluoride (PVDF) mem-
branes (Santa Cruz) were incubated with primary anti-
body at 4 ˚C for two days. Primary antibodies used for
western blots were as follows: rabbit anti-HIVEP2 sera
(dilution at 1:1000), mouse anti-glyceraldehyde-3-
phosphate dehydrogenase (GAPDH, 1:10,000, RRID
AB_10613283, Biolegend, for cells), mouse anti-GAPDH
(1:200, RRID AB_2107299, Santa Cruz, for rat brain), goat
anti-RNA Pol II (1:100, RRID AB_2167471, Santa Cruz,
for nuclear protein control), mouse anti-TH (1:1000,
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RRID AB_2201528, Millipore, for cytoplasm protein
control). Amersham ECL Western Blotting Analysis Sys-
tem (GE Healthcare) was used to detect the primary
antibody activity according to the manufacturer’s
instruction. The images were captured by the Bio-Rad
Molecular Imager (Bio-Rad, ChemiDOCIM XRS+) and
quantitative assessment of protein bands, using the area
under curve method, was executed by the Image J
Software (NIH).
Quantitative reverse transcription PCR (qRT-PCR)
For cells and rat tissues, RNA were extracted by TRIzol
(Ambion), following the manufacturer’s protocol. RNA
concentration was estimated with NanoDrop Lit (Thermo
Fisher Scientific). Two hundred nanograms of total RNAs
was reverse transcribed into cDNA by using the Verso
cDNA synthesis kit (Thermo scientific) with oligo dT
primers following the manufacturer’s protocol. cDNA was
diluted by 10 fold with DNase-free water. cDNA samples
were amplified in triplicates by incubation in the Bio-Rad
CFX Connect real-time system. The amplification con-
dition was 95 ˚C for 5 min, then for 49 cycles of 95 ˚C for
15 s, 55 ˚C for 20 s and 72 ˚C for 30 s using SsoAdvanced
Universal SYBR green supermix (Bio-Rad) in a final
volume of 12.5 μL, containing 1 μL of cDNA and a final
concentration of 0.5 μM of forward and reverse primers.
The gene of interest was then normalized against the
reference gene GAPDH. The relative expression of the
target gene was calculated according to the method as
previously described12.
Luc activity assay
Forty-eight hours after HIVEP2 overexpression or
DsiRNA co-transfected with reporter constructs, cell
lysates were collected for Luc activity assay and protein
concentration measurements. Luc activities were mea-
sured by Promega’s Luciferase Assay System with Bio-
Tek/Gen5 (Winooski). Protein assays were performed
with Coomassie blue according to the manufacturer’s
instructions (Thermoscientific). Briefly, 250 µL of Coo-
massie protein assay reagent was added to 5 µL of lysates
and BSA standards. Luc activity value to protein con-
centration ratios were calculated for statistical analysis.
Each assay was performed in duplicate.
Chromatin immunoprecipitation (ChIP) PCR and qPCR
ChIP method was described as before12. Around 5 ×
106 BE(2)-M17 cells or 100 mg of human brain tissue
were collected for ChIP assay. Tissue in 200 µL 1%
formaldehyde was homogenized with a pestle mixer
(Argos) and crosslinked at RT for 15 min. Indepen-
dently, cells were crosslinked with 1% formaldehyde at
RT for 10 min. The lysate was sonicated 12 cycles for BE
(2)-M17 cells or 24 cycles for brain tissues (30 s on and
30 s off). Supernatants were transferred into new tubes
and diluted 1:4 with Dilution Buffer (0.01% SDS, 1.1%
Triton X-100, 1.2 mM EDTA, 16.7 mM Tris-HCl, pH
8.0, 167 mM NaCl plus the protease inhibitors) and pre-
cleared with 25 µL Dynabeads Protein A (Invitrogen) at
4 ˚C for 2 h with gentle rotation. The cleared super-
natant was divided into two tubes and each incubated
with 10 µL anti-HIVEP2 sera or control rabbit serum at
4 ˚C for 48 h and then immunoprecipitated with 25 µL
Protein A beads on a rotator at 4 ˚C for 4 h. Five hun-
dred microliters of supernatant from the tube incubated
with control rabbit IgG was collected as Input. The
immunoprecipitates were washed sequentially with the
following buffers: low salt buffer (0.1% SDS, 1% Triton
X-100, 2 mM EDTA, 20 mM Tris-HCl pH 8.0, 150 mM
NaCl), high salt buffer (0.1% SDS, 1% Triton X-100,
2 mM EDTA, 20 mM Tris-HCl pH 8.0, 500 mM NaCl),
LiCl wash buffer (0.25 M LiCl, 1% Sodium deoxycholate,
1 mM EDTA, 10 mM Tris-HCl, pH 8.0), and TE (10 mM
Tris-HCl, 1 mM EDTA, pH8.0). DNA was then eluted
with 500 µL of elution buffer (1% SDS, 0.1 M NaHCO3)
and the crosslinking was reversed by adding 20 μl 5 M
NaCl and incubated at 65 °C overnight. 10 µL 0.5 M
EDTA, 40 µL 1M Tris-HCl (pH 6.8), and 2 µL 10 mg/
mL Proteinase K were added to each sample, followed
by incubation at 45 °C for 2 h to digest proteins. After
purification with PCR purification kit (Promega), DNA
including Input was recovered by 30 µL H2O and used
as templates for PCR with primers to amplify the
HIVEP2 binding site on SLC6A3. Beta-action (ACTB)
was included as a negative target control. The PCR
condition was 95 ˚C for 3 min, then 40 cycles of 95 ˚C
for 30 s, 56 ˚C for 30 s and 72 ˚C for 30 s, followed by
72 ˚C for 7 min, using PCR Master Mix (Thermo Sci-
entific) in a final volume of 20 μL, containing 1 µL of
eluted DNA as the template. For the negative control
ACTB, 0.5% DMSO was added into the PCR reaction
which contained 1 µL of eluted DNA as the template.
PCR products were resolved by 1.2% agarose electro-
phoresis and ethidium bromide-stained bands visualized
by the Chemi Doc XRS Molecular Imager. qPCR was
used to quantitate the binding activity.
Secondary analysis of dbGaP GWAS datasets
Three dbGaP GWAS datasets on SUD (all past their
embargo periods) and quality control have been reported
before13,24. Imputation, association tests, logistic
regression-based single nucleotide polymorphism (SNP)-
SNP interactions, and meta-analyses were conducted as
reported previously13,24. Both secondary data analysis of
dbGaP GWAS datasets and the use of human post mor-
tem brain tissue were approved by McLean Hospital
Institutional Review Board (IRB) and/or National Insti-
tutes of Health (NIH).
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Statistical analysis
Data were all presented as means ± standard error of
mean (SEM) where sample sizes were determined by
gene activity stability. Based on GraphPad Prism
(v5.04), two-way analysis of variance (ANOVA with
Bonferroni post hoc tests) or Student’s t-test results
with p values < 0.05 were considered as statistically
significant.
Results
By using the 121-bp of haplotype A as bait, many
potential clones were obtained. However, based on in-
frame fusions and adequate expression in DA neurons,
HIVEP2 was chosen as a potential DAergic TF for further
characterization in this study.
HIVEP2 was present in both cytoplasm and nucleus
Immunofluorescence staining with anti-HIVEP2 sera
localized this protein to both the cytoplasm and nuclei of
cultured cells and DA neurons (Fig. 1a, b). In the VTA,
most of the protein was expressed in DA neurons. To
exclude non-specific reactivity, Western blotting detected
the protein, based on its molecular weight, in both cyto-
plasmic and nuclear fractions of the VTA (Fig. 1c).
Greater protein levels were located in the cytoplasm than
in the nuclei, as determined by both in vitro and ex vivo
assays.
HIVEP2 physically bound to the 121-bp of Intron 1
Although this protein was cloned as a TF for the 121-bp
in yeast cells, the binding activity needed to be verified in
Fig. 1 HIVEP2 protein was expressed in nuclei. a DAergic cell line SK-N-AS showed nuclear expression of HIVEP2. b DA neurons in the ventral
tegmental area (VTA) of adult mouse brain showed nuclear expression of HIVEP2. Scale bar is 20 µm. c Western blotting showed that HIVEP2 can be
detected in nuclei of mouse VTA. RNA Pol II was used as a nuclear marker and TH, a cytoplasmic marker
Fig. 2 HIVEP2 bound to the promoter domain of human SLC6A3. a Regular PCR of ChIP showed that anti-HIVEP2 sera can specifically pull down
the 121-bp binding domain on Intron 1 of SLC6A3, but neither the +0.79 kb locus which was also in Intron 1 and 1 kb away from 121-bp nor the
ACTB gene. The ChIPs were done on BE(2)-M17 cell line and two human post mortem brain nigral samples: HSN1895 (a 93-year old healthy female)
and HSN1807 (a 59-year old healthy male). b Quantification showed fold enrichment by anti-HIVEP2 sera. *p < 0.05; **p < 0.01 (ANOVA Bonferroni
post hoc tests, n= 3)
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human cells. To do this three types of samples were used:
the neuroblastoma cell line BE(2)-M17 of human origin as
a cellular model for DA neurons, and post mortem nigral
tissue from two healthy subjects, HSN1895, HSN1807.
The present results from a ChIP analysis showed that
anti-HIVEP2 was able to pull down the 121-bp selectively
in all three samples (Fig. 2). This result confirmed the
Y1H result and supported HIVEP2 as a TF in DA
neurons.
Overexpression of HIVEP2 upregulated endogenous
SLC6A3 activity
In the human neuroblastoma SK-N-AS cells which
served as another model for DA neurons22, over-
expression of pcDNA3.1+HIVEP2 increased the
HIVEP2 protein levels as determined by Western blot-
ting (Fig. 3a), verifying both the cDNA clone and the
anti-HIVEP2 sera. Next, it was determined whether the
overexpression could regulate endogenous SLC6A3 gene
activity in these cellular models. In BE(2)-M17 cells, the
overexpression upregulated SLC6A3 mRNA levels by
52% (Fig. 3b). In SK-N-AS cells, the overexpression
upregulated SLC6A3 mRNA levels by 30% (Fig. 3c); and
the upregulation went up to 44% after the cells were
treated with hexyl-4-pentynoic acid (HPA), an HDAC
inhibitor25 (Fig. 3d). In this study, manipulating HIVEP2
expressions had no effect on GAPDH levels, which
allowed the use of GAPDH as an internal control. These
findings indicated that HIVEP2 acted as a trans-
activator of SLC6A3 in these cells, which was con-
sistent with the cloning, the nuclear expression and the
121-bp binding results.
HIVEP2 targeted specific DNA sequences of Intron 1
A previous study showed that GGGCCTTTCC was the
binding motif or consensus sequence (CS) of HIVEP226.
Two homologous sequences were found in the 121-bp,
“1” and “2”, which were 54 bp apart from each other. “2”
contained two dinucleotide polymorphism (DNPi or
rs67175440) alleles13,27, A and B, sharing 50–70% identity
with CS (Fig. S1a: “A” defined the haplotype of the bait
121-bp). Luc-reporting analysis showed that over-
expression of HIVEP2 could upregulate the SV40 pro-
moter in a “1”- or “2”-dependent manner (Fig. S1b). The
results also identified a DsiRNA molecule that could
downregulate endogenous HIVEP2 protein expression
(Fig. S1c). As a result, this knockdown caused Luc activity
reduction to 0.63-fold via “1” as well as to 0.70-fold via
“2A” and “2B”. That is, this HIVEP2 DsiRNA could
downregulate the SV40 promoter in a “1”- or “2”-depen-
dent manner. These in vitro results suggested that
HIVEP2 regulates SLC6A3 activity via binding to
GTGGCTTTCT, or to a lesser extent, TTGCCTCTCC or
TTGCTCCTCC, documenting the actual sequence(s) in
the Intron-1 region bound by HIVEP2.
Sex-dependent alteration of HIVEP2 expression in the P
versus NP rat model
P rats display excessive substance (alcohol and other
drugs) taking and meet criteria proposed for a valid ani-
mal model of SUD. These rats were selected on the basis
of their daily free choice intake of 10% ethanol solution vs.
water, and on their preference for the alcohol solution
over water. As a consequence, they also show increased
responses to some other drugs of abuse28,29. To determine
potential association between HIVEP2 and SUD, HIVEP2
activity was investigated in the VTA of naive P vs NP rats,
an animal model of DAergic pathology30–34, using both
males and females. The results showed sex-dependence,
with activity at both mRNA and protein levels being sig-
nificantly higher in male P rats compared with male NP
rats, whereas significantly lower in female P rats com-
pared with female NP rats (Fig. 4). We also have looked at
two other recently cloned TFs, SRP54, and Nfe2l112, and
found that neither showed >50% changes in the males or
any significant changes in the females (protein data not
shown here), indicating a selective role of HIVEP2 in the
genomic etiology of SUD. These data supported our
hypothesis that HIVEP2 can confer a risk to develop SUD,
although an important finding was that this effect
appeared to be sex-dependent.
Fig. 3 Overexpression of HIVEP2 upregulated endogenous mRNA
level of SLC6A3 in cultured BE(2)-M17 and SK-N-AS cells. a HIVEP2
overexpression confirmed by Western Blotting via SK-N-AS. b HIVEP2
overexpression increased the mRNA level of SLC6A3 in BE(2)-M17 (n= 3,
p= 0.019 by t-tests). c, d HIVEP2 overexpression increased the mRNA
level of SLC6A3 in SK-N-AS cells without (c: n= 3, p= 0.004) or with
HPA 5 µm overnight treatment (d: n= 4, p < 0.0001)
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Significant interactions and large effect size epistasis
between HIVEP2 and SLC6A3 in SUD
To validate a clinical relevance of the significant find-
ings in the rat model, we consulted with the dbGaP
GWAS datasets from four cohorts with SUD, as described
before13. Based on meta-analysis of logistic regression
case-control association results from the four cohorts of
unrelated individuals, we have found that there are
>1200 significant including more than 300 absolute
genome-wide significant interactions between HIVEP2
and SLC6A3 in the genetic etiology of SUD (Fig. 5, top
ones detailed in Table S1; “absolute” means Bonferroni
correction by all base-pairs of the human genome). These
interactions are much more significant than the reported
ones between the downregulator’s gene AZI23’UTR and
SLC6A313. For example, rs12525545 in Intron 3 of
HIVEP2 interacted with rs748209 located in a distal
(−12 kb) promoter region of SLC6A3 with a pmeta value of
1.12 × 10−37 and an odds ratiometa of 0.16. However, there
were no significant main effects, that is, allelic associations
between HIVEP2 and SUD (Table S2), with males show-
ing stronger signals than females (details not shown here).
There appears to be three rather distinct regions in
SLC6A3 where the interactions occur but none of pre-
viously used markers were located within the two CSs so
that the epistatic signals came likely from linkage
disequilibrium.
Discussion
The present study identified HIVEP2, as a new DAergic
TF, and has demonstrated that it binds to SLC6A3 and
regulates SLC6A3 activity, which is the hallmark of
DAergic neurons. The findings also revealed that altered
HIVEP2 activity may be associated with vulnerability for
developing SUD; such that altered expression levels were
associated with this phenotype in the P vs NP animal
model of SUD (alcohol, nicotine, and cocaine)30–34. There
seem substantial sex differences in ethanol responses in P
rats. It has been reported that the males show significantly
higher preference to 8% ethanol than the females during a
period of 90 days35. We have also observed that in an
adolescent binge drink model, the males show higher
consumption than the females36. These behavioral data fit
with our finding that elevated HIVEP2 expression in
males be a risk factor for AUD in males. Due to limita-
tions of cultured assay systems and of manipulating the
large HIVEP2 gene (10 kb), these in vitro results did not
necessarily represent the in vivo effect sizes but the
functional human molecular genetic findings may help
delineate disease mechanisms in humans.
Previous study showed that the 121-bp of haplotype A,
especially a 36 bp subfragment containing the HIVEP2
target “1”, displayed inhibitory activity only on the SV40
promoter22. It was an expectation that we would be able
to clone a trans-repressor, instead of a trans-activator
(HIVEP2). Therefore, it remains unknown what mediated
the inhibitory activity of 121-bp. One possibility was that
the long non-coding RNA (lncRNA) AZI23’UTR was
contributing to the inhibitory activity. Another possibility
was that the activation-based Y1H system was unable to
clone such as a repressor so that other approaches might
need to be considered.
HIVEP2 (also known as Schnurri-2) was initially cloned
as a zinc finger protein binding to the human immuno-
deficiency virus type (HIV-1) enhancer and to an
enhancer of major histocompatibility complex class I
genes26,37. This category of TFs are supposed to be
expressed primarily in the nuclei but our data suggest that
they also are localized to the cytoplasm with unknown
function. Lately, this protein has been related to brain
function. The gene knockout mice display hyperactivity38,
consistent with a view that HIVEP2 is an activator of
SLC6A3. These mice also display schizophrenia-related
phenotypes, increased anxiety, intellectual disability, and
memory deficits39–43. However, until the present study its
activity has not been tested in the context of a vulner-
ability to develop SUD.
The epistatic association significances were much larger
than those for AZI23'UTR13 but it remains unclear where
the epistasis signals came from in the meta-analysis of
case-control associations with SUD (also alcohol, nicotine
Fig. 4 HIVEP2 expression in VTA (upper panels for mRNA, lower
panels for protein) showed significant differences between NP
and P rats, males (a) and females (b). Representative Western blots
are shown in the middle panels and quantification, in lower panels;
GAPDH was used as input controls; t-tests: *p < 0.05; **p < 0.01 (t-tests,
n= 4–5)
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and cocaine). The HIVEP2 target sequences in the 121-bp
carried two known polymorphisms, DNPi (rs2937640 and
rs2975223) and rs28382220, both were located in the “2”
sequences which may have contributed to some of the
observed significant epistasis but none of these SNPs were
included in the previous GWAS datasets; target sequence
“1” carried no known polymorphism. Nevertheless, there
was the possibility of “synthetic associations” in the
observed associations44,45. Based on the epistasis, HIVEP2
could bind to other loci including the distal promoter
regions of SLC6A3.
A main limitation of this study is that the observed
associations do not necessarily indicate causation. To
address this, protein-DNA binding activity and associated
phenotypes related to SUD could be studied in gene
knockout mice. Another unknown is the level of SLC6A3-
wide, or even genome-wide, binding activity of HIVEP2 in
DA neurons. In addition, gene and/or protein activity has
not been studied comprehensively in a brain-region-
specific manner. Nor has its function been studied in the
cytoplasmic fraction. These limitations warrant further
investigations.
Conclusions
HIVEP2 is a new DAergic TF expressed in both cyto-
plasm and nuclei. Altered HIVEP2 activity in the VTA is
associated with SUD in a rat model; significant HIVEP2-
SLC6A3 epistasis is found for SUD in humans. These data
suggest that regulated HIVEP2 in DA neurons of reward
pathways may modulate vulnerability to develop SUD.
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Fig. 5 Human genetics of SUD via SNP interactions (colored curves) between HIVEP2 (on the right) and SLC6A3 (on the left; 121-bp:
location indicated by blue diamond). Data are from meta-analysis of logistic regression results by using three dbGaP datasets of SUD (alcohol and
cigarette smoking). Gray horizontal bars, on the left is SLC6A3 in chr5 and on the right is HIVEP2 in chr6 with coordinates indicated above the bars;
double black arrow symbols, location of transcription start and ending sites (both genes run on the minus strands of the chromosomes);
thermometer bar on the right, interaction strength (p-value from meta-analysis) in the form of –Log10(p-value); only shown are those reaching
absolute genome-wide significance (p < 10−20); chromosomal scale: 10 kb
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